Data Sheet 1_Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.docx

Citation searching of all included studies was performed for additional eligible studies. Duplicate title/abstract screening, data extraction and risk of bias assessments were conducted.</p>Results<p>A total of 135 studies were included in the review, 66.7% (90/135) of which studied recurrent glioblastoma. Studies included 9,029 patients, 51.1% (4612/9029) of which were male.

A total of 47 different RTK-directed therapies were assessed. Multikinase inhibitors (40.7%, 55/135), EGFR-directed therapies (28.9%, 39/135) and VEGFR inhibitors (20%, 27/135) were the most studied therapies. An additional 6.7% (9/135) of studies investigated combined EGFR-directed therapy and VEGFR inhibition.

A total of 4.4% (6/135) of studies demonstrated a statistically significant survival benefit, whilst therapies appeared beneficial to survival in an additional 11.1% (15/135) of studies. There was no consistent evidence supporting survival efficacy for any RTK-directed therapy.</p>Conclusion<p>Whilst there is no strong evidence for survival benefit of any RTK-directed therapy, there are encouraging results in a small proportion of studies.

Future directions include identifying and validating novel biomarkers, standardising reporting, and improving clinical trial design to produce more robust and interpretable data.</p>Systematic Review Registration<p>PROSPERO CRD42022366607.</p>